• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

天然萘并吡喃酮-大环内酯类杂种的发现、全合成及抗炎活性评价作为强效 NLRP3 炎性体抑制剂。

Discovery, Total Synthesis, and Anti-Inflammatory Evaluation of Naturally Occurring Naphthopyrone-Macrolide Hybrids as Potent NLRP3 Inflammasome Inhibitors.

机构信息

Key Laboratory of Marine Drugs, Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, 266100, China.

Laboratory for Marine Drugs and Bioproducts, Qingdao National Laboratory for Marine Science and Technology, Qingdao, 266237, China.

出版信息

Angew Chem Int Ed Engl. 2024 Oct 21;63(43):e202405860. doi: 10.1002/anie.202405860. Epub 2024 Jul 17.

DOI:10.1002/anie.202405860
PMID:38837604
Abstract

Numerous clinical disorders have been linked to the etiology of dysregulated NLRP3 (NACHT, LRR, and PYD domain-containing protein 3) inflammasome activation. Despite its potential as a pharmacological target, modulation of NLRP3 activity remains challenging. Only a sparse number of compounds have been reported that can modulate NLRP3 and none of them have been developed into a commercially available drug. In this research, we identified three potent NLRP3 inflammasome inhibitors, gymnoasins A-C (1-3), with unprecedented pentacyclic scaffolds, from an Antarctic fungus Pseudogymnoascus sp. HDN17-895, which represent the first naturally occurring naphthopyrone-macrolide hybrids. Additionally, biomimetic synthesis of gymnoasin A (1) was also achieved validating the chemical structure and affording ample amounts of material for exhaustive bioactivity assessments. Biological assays indicated that 1 could significantly inhibited in vitro NLRP3 inflammasome activation and in vivo pro-inflammatory cytokine IL-1β release, representing a valuable new lead compound for the development of novel therapeutics with the potential to inhibit the NLRP3 inflammasome.

摘要

已有大量临床疾病被认为与 NLRP3(NACHT、LRR 和 PYD 结构域包含蛋白 3)炎性小体激活的失调有关。尽管 NLRP3 作为药理学靶点具有很大的潜力,但调控其活性仍然具有挑战性。目前仅有少数几种能够调节 NLRP3 的化合物被报道,而且它们都没有被开发成商业上可用的药物。在这项研究中,我们从南极真菌 Pseudogymnoascus sp. HDN17-895 中发现了三种具有前所未有的五环骨架的强效 NLRP3 炎性小体抑制剂,gymnoasins A-C(1-3),它们代表了第一个天然存在的萘并吡喃酮-大环内酯类杂种。此外,还通过仿生合成获得了 gymnoasin A(1),验证了其化学结构,并提供了大量的材料进行全面的生物活性评估。生物测定表明,1 可显著抑制体外 NLRP3 炎性小体激活和体内促炎细胞因子 IL-1β 的释放,代表了一种有价值的新型先导化合物,可用于开发具有抑制 NLRP3 炎性小体潜力的新型治疗药物。

相似文献

1
Discovery, Total Synthesis, and Anti-Inflammatory Evaluation of Naturally Occurring Naphthopyrone-Macrolide Hybrids as Potent NLRP3 Inflammasome Inhibitors.天然萘并吡喃酮-大环内酯类杂种的发现、全合成及抗炎活性评价作为强效 NLRP3 炎性体抑制剂。
Angew Chem Int Ed Engl. 2024 Oct 21;63(43):e202405860. doi: 10.1002/anie.202405860. Epub 2024 Jul 17.
2
Discovery of dronedarone and its analogues as NLRP3 inflammasome inhibitors with potent anti-inflammation activity.发现具有强效抗炎活性的 NLRP3 炎性体抑制剂决奈达隆及其类似物。
Bioorg Med Chem Lett. 2021 Aug 15;46:128160. doi: 10.1016/j.bmcl.2021.128160. Epub 2021 May 29.
3
Design, synthesis and biological evaluation of novel diphenylamine analogues as NLRP3 inflammasome inhibitors.新型二苯胺类似物作为 NLRP3 炎性小体抑制剂的设计、合成与生物评价。
Bioorg Med Chem. 2024 Nov 1;113:117927. doi: 10.1016/j.bmc.2024.117927. Epub 2024 Sep 18.
4
Geranylgeranyl diphosphate synthase 1 knockdown suppresses NLRP3 inflammasome activity via promoting autophagy in sepsis-induced acute lung injury.香叶基香叶基二磷酸合酶 1 敲低通过促进脓毒症诱导的急性肺损伤中的自噬来抑制 NLRP3 炎性体活性。
Int Immunopharmacol. 2021 Nov;100:108106. doi: 10.1016/j.intimp.2021.108106. Epub 2021 Sep 13.
5
Development of Novel Tetrahydroquinoline Inhibitors of NLRP3 Inflammasome for Potential Treatment of DSS-Induced Mouse Colitis.新型四氢喹啉 NLRP3 炎性小体抑制剂的开发用于潜在治疗 DSS 诱导的小鼠结肠炎。
J Med Chem. 2021 Jan 14;64(1):871-889. doi: 10.1021/acs.jmedchem.0c01924. Epub 2020 Dec 17.
6
Hit-to-Lead Optimization of the Natural Product Oridonin as Novel NLRP3 Inflammasome Inhibitors with Potent Anti-Inflammation Activity.天然产物冬凌草甲素作为新型 NLRP3 炎性小体抑制剂的从头至 Lead 优化及其强效抗炎活性。
J Med Chem. 2024 Jun 13;67(11):9406-9430. doi: 10.1021/acs.jmedchem.4c00504. Epub 2024 May 15.
7
A Synthetic Small Molecule F240B Decreases NLRP3 Inflammasome Activation by Autophagy Induction.一种合成小分子F240B通过诱导自噬降低NLRP3炎性小体激活。
Front Immunol. 2020 Dec 18;11:607564. doi: 10.3389/fimmu.2020.607564. eCollection 2020.
8
Identification and Validation of PKR as a Direct Target for the Novel Sulfonamide-Substituted Tetrahydroquinoline Nonselective Inhibitor of the NLRP3 Inflammasome.鉴定和验证 PKR 作为新型磺胺取代的四氢喹啉 NLRP3 炎症小体非选择性抑制剂的直接靶标。
J Med Chem. 2024 Jun 27;67(12):10168-10189. doi: 10.1021/acs.jmedchem.4c00343. Epub 2024 Jun 10.
9
Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease.白细胞介素-1 和炎症小体作为心血管疾病的治疗靶点。
Circ Res. 2020 Apr 24;126(9):1260-1280. doi: 10.1161/CIRCRESAHA.120.315937. Epub 2020 Apr 23.
10
Design, Synthesis and Evaluation of Oxazaborine Inhibitors of the NLRP3 Inflammasome.设计、合成及评估 NLRP3 炎症小体的噁嗪硼烷抑制剂。
ChemMedChem. 2018 Feb 20;13(4):312-320. doi: 10.1002/cmdc.201700731. Epub 2018 Feb 5.

引用本文的文献

1
New bioactive secondary metabolites from fungi: 2024.来自真菌的新型生物活性次级代谢产物:2024年。
Mycology. 2025 Jul 11;16(3):961-987. doi: 10.1080/21501203.2025.2526772. eCollection 2025.
2
Polyketide Derivatives from the Mangrove-Derived Fungus sp. HDN15-312.来源于红树林真菌 sp. HDN15-312 的聚酮化合物衍生物。
Mar Drugs. 2024 Aug 8;22(8):360. doi: 10.3390/md22080360.